Literature DB >> 16631367

Chronic inflammatory demyelinating polyneuropathy.

Gérard Said1.   

Abstract

Chronic inflammatory demyelinative polyneuropathy (CIDP) is an acquired neuropathy, presumably of immunological origin. Its clinical presentation and course are extremely variable. CIDP is one of the few peripheral neuropathies amenable to treatment. Typical cases associate progressive or relapsing-remitting motor and sensory deficit with increased CSF protein content and electrophysiological features of demyelination. In other instances the neuropathy is predominantly or exclusively motor or sensory, CSF normal and electrophysiological studies fail to show evidence of demyelination. In such cases conventional diagnostic criteria are not filled yet the patient may respond to immunomodulatory treatments. In this paper we review the diagnostic pitfalls and clinical variants of CIDP to illustrate the problems that may arise. The different therapeutic options are reviewed. Axon loss associated with demyelination is the most important factor of disability and resistance to treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631367     DOI: 10.1016/j.nmd.2006.02.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

1.  Chronic inflammatory demyelinating polyneuropathy: evaluation of the vestibular system with cervical and ocular vestibular evoked myogenic potentials.

Authors:  Giuseppe Magliulo; Giannicola Iannella; Alessandra Manno; Laura Libonati; Emanuela Onesti; Annarita Vestri; Danilo Alunni Fegatelli; Diletta Angeletti; Annalisa Pace; Giampiero Gulotta; Silvia Gagliardi; Maurizio Inghilleri
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-27       Impact factor: 2.503

Review 2.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

3.  A case of cauda equina syndrome in early-onset chronic inflammatory demyelinating polyneuropathy clinically similar to charcot-marie-tooth disease type 1.

Authors:  Seung Eun Lee; Seung Won Park; Sam Yeol Ha; Taek Kyun Nam
Journal:  J Korean Neurosurg Soc       Date:  2014-06-30

4.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

5.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

6.  Lightning can strike twice: an unlucky patient of neurological interest.

Authors:  Ebony S Gilbee
Journal:  BMJ Case Rep       Date:  2013-06-24

Review 7.  Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.

Authors:  Richard J Bright; Jenny Wilkinson; Brendon J Coventry
Journal:  BMC Neurol       Date:  2014-02-07       Impact factor: 2.474

8.  Electrophysiological evaluation of chronic inflammatory demyelinating polyneuropathy and charcot-marie-tooth type 1: dispersion and correlation analysis.

Authors:  Ji Hyuk Kang; Hye Jeong Kim; Eun Ryeong Lee
Journal:  J Phys Ther Sci       Date:  2013-11-20

9.  Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient.

Authors:  Delphine Renard; Thierry Gauthier; Jean-Pierre Venetz; Thierry Buclin; Thierry Kuntzer
Journal:  Clin Kidney J       Date:  2012-08

Review 10.  A comprehensive review of amyotrophic lateral sclerosis.

Authors:  Sara Zarei; Karen Carr; Luz Reiley; Kelvin Diaz; Orleiquis Guerra; Pablo Fernandez Altamirano; Wilfredo Pagani; Daud Lodin; Gloria Orozco; Angel Chinea
Journal:  Surg Neurol Int       Date:  2015-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.